Dimethyltriazenoimidazole carboxamide therapy of islet cell carcinoma of the pancreas
| Autor: | Michael E. Peetz, Alan E. Awrich, William S. Fletcher |
|---|---|
| Rok vydání: | 1981 |
| Předmět: |
Adult
Male medicine.medical_specialty Dacarbazine Glucagonoma Gastroenterology Glucagon Internal medicine medicine Humans Aged geography geography.geographical_feature_category business.industry General Medicine Middle Aged Necrolytic migratory erythema Adenoma Islet Cell medicine.disease Islet Pancreatic Neoplasms Diarrhea medicine.anatomical_structure Endocrinology Oncology Female Surgery medicine.symptom Every Four Weeks Pancreas business medicine.drug |
| Zdroj: | Journal of Surgical Oncology. 17:321-326 |
| ISSN: | 1096-9098 0022-4790 |
| DOI: | 10.1002/jso.2930170404 |
| Popis: | Four patients with metastatic glucagonoma and one patient with metastatic diarrheogenic islet cell carcinoma of the pancreas were treated with dimethyltriazenoimidazole carboxamide (DTIC), 250 mg/M2 daily for five days repeated every four weeks. All patients responded clinically and chemically in one or more ways by a reduction in plasma glucagon levels, improved glucose tolerance, decreased measureable tumor, weight gain, and resolution of necrolytic migratory erythema and diarrhea. This experience and other cases from the literature call for the investigation of DTIC as the initial therapy in metastatic islet cell carcinoma of the pancreas and as being of possible benefit in other tumors of neuroendocrine origin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text